Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug

TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip